CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lisdexamfetamine dimesylate

Last Updated: July 10, 2009
Result type: Reports
Project Number: SR0171-000
Product Line: Reimbursement Review

Generic Name: Lisdexamfetamine dimesylate

Brand Name: Vyvanse

Manufacturer: Shire Canada Inc.

Therapeutic Area: Attention deficit hyperactivity disorder

Indications: Attention deficit hyperactivity disorder

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 18, 2009

Recommendation Type: Do not list